Management of medication errors in oncological patients: A cross-sectional study and case reports of pharmaceutical interventions in a university hospital in central-west Brazil

IntroductionAntineoplastic chemotherapy (ACT) is widely used, but involves significant risks due to protocol complexity and inherent toxicity. Pharmacists play a key role in validating ACT prescriptions to enhance patient safety.ObjectiveTo analyze medication errors during ACT prescribing and describe pharmaceutical interventions performed to manage these errors at a Federal University Hospital in the Central-West region of Brazil.MethodologyThis cross-sectional study, supplemented with case reports, was conducted between January 2023 and July 2024. A total of 382 prescriptions for 208 oncology outpatients were analyzed; only prescriptions with previously identified medication errors were included in this study. Medication errors were classified as decision-making or writing errors according to the Pharmaceutical Care Network Europe (PCNE) classification and Dean et al. (2000), and categorized by severity using the NCC MERP framework. Data were extracted from an institutional database and validated by an oncology specialist pharmacist. Only deviations with potential pharmacological or clinical impact were classified as decision-making errors, excluding minor operational adjustments.ResultsDecision-making errors occurred in 91.6% (n = 358/391) of prescriptions, primarily due to inappropriate diluent volumes (91%), while writing errors were observed in 8.4% (n = 36/391), mainly from missing clinical information. Pharmaceutical interventions were accepted in 99% of cases, preventing errors from reaching patients. Most errors were intercepted before administration (NCC MERP Category B), though two cases had potential clinical consequences (Category C) and one required patient monitoring due to communication issues (Category D).ConclusionSpecialized oncology pharmacists play a critical role in ensuring the safety of ACT prescribing. The high proportion of decision-making errors observed within this selected sample emphasizes the need for systemic improvements, such as integrated electronic prescribing and continuous pharmacist-led oversight, to reduce preventable errors and enhance patient safety.

Authors

Institutions

Publication Details

Journal
Journal of Oncology Pharmacy Practice
Published
2026-04-22
DOI
https://doi.org/10.1177/10781552261444589
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Management of medication errors in oncological patients: A cross-sectional study and case reports of pharmaceutical interventions in a university hospital in central-west Brazil

A Araújo Lopes, Renato Rocha Martins, Paulo Augusto Souza Fernandes, Esther Domenici Mozzer Pontes
Journal of Oncology Pharmacy Practice
Pharmaceutical Practices and Patient Outcomes
article

Management of medication errors in oncological patients: A cross-sectional study and case reports of pharmaceutical interventions in a university hospital in central-west Brazil

A Araújo Lopes, Renato Rocha Martins, Paulo Augusto Souza Fernandes, Esther Domenici Mozzer Pontes
article en

Abstract

IntroductionAntineoplastic chemotherapy (ACT) is widely used, but involves significant risks due to protocol complexity and inherent toxicity. Pharmacists play a key role in validating ACT prescriptions to enhance patient safety.ObjectiveTo analyze medication errors during ACT prescribing and describe pharmaceutical interventions performed to manage these errors at a Federal University Hospital in the Central-West region of Brazil.MethodologyThis cross-sectional study, supplemented with case reports, was conducted between January 2023 and July 2024. A total of 382 prescriptions for 208 oncology outpatients were analyzed; only prescriptions with previously identified medication errors were included in this study. Medication errors were classified as decision-making or writing errors according to the Pharmaceutical Care Network Europe (PCNE) classification and Dean et al. (2000), and categorized by severity using the NCC MERP framework. Data were extracted from an institutional database and validated by an oncology specialist pharmacist. Only deviations with potential pharmacological or clinical impact were classified as decision-making errors, excluding minor operational adjustments.ResultsDecision-making errors occurred in 91.6% (n = 358/391) of prescriptions, primarily due to inappropriate diluent volumes (91%), while writing errors were observed in 8.4% (n = 36/391), mainly from missing clinical information. Pharmaceutical interventions were accepted in 99% of cases, preventing errors from reaching patients. Most errors were intercepted before administration (NCC MERP Category B), though two cases had potential clinical consequences (Category C) and one required patient monitoring due to communication issues (Category D).ConclusionSpecialized oncology pharmacists play a critical role in ensuring the safety of ACT prescribing. The high proportion of decision-making errors observed within this selected sample emphasizes the need for systemic improvements, such as integrated electronic prescribing and continuous pharmacist-led oversight, to reduce preventable errors and enhance patient safety.

Journal of Oncology Pharmacy Practice
Universidade Federal de Goiás (BR)
Peace, Justice and strong institutions
Openalex Percentile: Top 7%
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.